{"filing":{"accession_number":"0001554855-26-001482","cik":"0000888721","ticker":"TRIB","company_name":"TRINITY BIOTECH PLC","form":"6-K","filing_date":"2026-07-02","report_date":null,"primary_document":"MainDocument.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/888721/000155485526001482/MainDocument.htm"},"events":[{"id":15699,"run_id":13998,"accession_number":"0001554855-26-001482","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces clinical trial results validating Trinity Biotech's CGM+ wearable biosensor technology's ability to distinguish nocturnal compression-related false lows from true blood glucose lows, based on analysis of over 5,000 hours of clinical wear data. The disclosure demonstrates a material product development milestone and technological differentiation within the $15 billion global CGM market, supporting the company's commercial strategy for its next-generation platform. While not a discrete M\u0026A, financing, or governance event, this operational milestone regarding a key product capability would affect a reasonable investor's assessment of the company's competitive positioning and commercialization prospects.","company_name":"TRINITY BIOTECH PLC","ticker":"TRIB","filing_date":"2026-07-02","form":"6-K","submitted_at":null,"items":[{"id":13573,"accession_number":"0001554855-26-001482","item_number":"EX-99.1","item_title":"ex991_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces clinical trial results validating Trinity Biotech's CGM+ wearable biosensor technology's ability to distinguish nocturnal compression-related false lows from true blood glucose lows, based on analysis of over 5,000 hours of clinical wear data. The disclosure demonstrates a material product development milestone and technological differentiation within the $15 billion global CGM market, supporting the company's commercial strategy for its next-generation platform. While not a discrete M\u0026A, financing, or governance event, this operational milestone regarding a key product capability would affect a reasonable investor's assessment of the company's competitive positioning and commercialization prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T12:31:09.535240+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13573,"accession_number":"0001554855-26-001482","item_number":"EX-99.1","item_title":"ex991_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces clinical trial results validating Trinity Biotech's CGM+ wearable biosensor technology's ability to distinguish nocturnal compression-related false lows from true blood glucose lows, based on analysis of over 5,000 hours of clinical wear data. The disclosure demonstrates a material product development milestone and technological differentiation within the $15 billion global CGM market, supporting the company's commercial strategy for its next-generation platform. While not a discrete M\u0026A, financing, or governance event, this operational milestone regarding a key product capability would affect a reasonable investor's assessment of the company's competitive positioning and commercialization prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T12:31:09.535240+00:00","company_name":"TRINITY BIOTECH PLC","ticker":"TRIB","filing_date":"2026-07-02"}]}